Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919917 | 0.77 | CYP1A2 (0.39) | HSP90AA1TRAP1 | |
| SCHEMBL2786539 | 0.77 | PDE1A (0.42) | ALDH1A1HSP90AA1TRAP1 | |
| SCHEMBL21788663 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSP90AA1TRAP1LMNATP53 | |
| SCHEMBL17926576 | 0.75 | HSP90AA1 (0.39) | ALDH1A1HSP90AA1TRAP1MAPTTDP1 | |
| SCHEMBL30095837 | 0.75 | PDE2A (0.39) | — | |
| SCHEMBL11909416 | 0.75 | KMO (0.46) | ALDH1A1HSP90AA1TRAP1LMNATP53 | |
| SCHEMBL2189832 | 0.74 | ADORA3 (0.43) | ALDH1A1HSP90AA1TRAP1LMNATP53 | |
| SCHEMBL30748233 | 0.73 | — | — | |
| SCHEMBL12137539 | 0.72 | — | — | |
| SCHEMBL13896214 | 0.71 | PDE2A (0.37) | HSP90AA1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | ALDH1A1 4705/4885HSP90AA1 1187/4885TRAP1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.